TMOTMO
US • —
$501.36
P/E
27.59
PEG
4.12
FCF Yield
—
Rev Growth YoY
+5.4% YoY
Gross Margin
40.9%
Health Score
7/10
D/E Ratio
0.74
Confidence
LOW
Business Snapshot
Thermo Fisher Scientific is the global leader in serving science, providing a comprehensive range of analytical instruments, lab equipment, consumables, reagents, software, and services to pharmaceutical, biotech, academic, and diagnostic customers. Its diverse portfolio is anchored by major segments like Life Sciences Solutions, Analytical Instruments, and Laboratory Products and Biopharma Services, which together create a highly diversified revenue base. The company operates in the highly fragmented life sciences tools and diagnostics market, holding a dominant competitive position as a one-stop-shop for research and production needs. Its defining characteristic is its massive scale and breadth, creating a unique competitive moat through customer stickiness and cross-selling opportunities across a vast installed base.
Financial Health
Gross margin stands at 40.9%, but the absence of a prior-year comparison prevents an assessment of trend; net margin of 15.2% reflects a fundamentally profitable business model. The balance sheet is healthy, with a debt/equity ratio of 0.74x, indicating moderate leverage, and a current ratio of 1.89x, suggesting adequate short-term liquidity...
Risk Assessment
- VALUATION — P/E of 27.59x trades at a 25% premium to the sector average of 22x, suggesting a rich valuation that already bakes in strong expectations.
- VALUATION DIVERGENCE — Both the FMP DCF fair value and the Python DCF estimate are unavailable or not calculable, removing a key intrinsic valuation anchor.
- EARNINGS QUALITY — Despite 4/4 earnings beats, the modest 6.7% earnings growth combined with a 27.59x P/E creates a high-growth premium paid for a non-growth earnings profile.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA GAP — Free cash flow data is unavailable, impairing the ability to assess cash generation efficiency and the sustainability of the current valuation....
Gross margin stands at 40.9%, but the absence of a prior-year comparison prevents an assessment of trend; net margin of 15.2% reflects a fundamentally profitable business model. The balance sheet is healthy, with a debt/equity ratio of 0.74x, indicating moderate leverage, and a current ratio of 1.89x, suggesting adequate short-term liquidity. Free cash flow data is unavailable, preventing a direct assessment of cash generation quality or FCF yield. Return on equity is a solid 13.2%, demonstrating the company's ability to generate returns on shareholder capital. Overall, Thermo Fisher exhibits strong profitability and a sound balance sheet, though the lack of cash flow data leaves a gap in assessing its true financial capacity for reinvestment or shareholder returns.
- VALUATION — P/E of 27.59x trades at a 25% premium to the sector average of 22x, suggesting a rich valuation that already bakes in strong expectations. - VALUATION DIVERGENCE — Both the FMP DCF fair value and the Python DCF estimate are unavailable or not calculable, removing a key intrinsic valuation anchor. - EARNINGS QUALITY — Despite 4/4 earnings beats, the modest 6.7% earnings growth combined with a 27.59x P/E creates a high-growth premium paid for a non-growth earnings profile. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA GAP — Free cash flow data is unavailable, impairing the ability to assess cash generation efficiency and the sustainability of the current valuation.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives